Septerna (NASDAQ:SEPN) Director Alan Ezekowitz Sells 81,820 Shares of Stock

Key Points

• Septerna Director Alan Ezekowitz sold 81,820 shares for about $3.93 million, reducing his direct ownership by 69.68% to 35,600 shares.
• The company missed quarterly estimates, reporting a loss of $0.57 per share versus the $0.42 loss expected, and revenue of $18.88 million versus $20.78 million forecast.
• Analysts have a Moderate Buy consensus and an average price target of $56.44; shares traded at $42.60 in the article’s cited session.

Septerna, Inc. (NASDAQ:SEPN - Get Free Report) Director Alan Ezekowitz sold 81,820 shares of the stock in a transaction on Wednesday, November 11th. The stock was sold at an average price of $48.09, for a total value of $3,934,723.80. Following the completion of the sale, the director directly owned 35,600 shares in the company, valued at approximately $1,712,004. This represents a 69.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Septerna Stock Performance

Shares of SEPN traded up $0.74 during trading hours on Friday, hitting $42.60. The company had a trading volume of 337,791 shares, compared to its average volume of 421,986. The stock has a market capitalization of $2.03 billion, a price-to-earnings ratio of -33.02 and a beta of 2.20. The firm has a fifty day moving average price of $40.46 and a 200-day moving average price of $33.12. Septerna, Inc. has a 52-week low of $19.69 and a 52-week high of $53.34.

Septerna (NASDAQ:SEPN - Get Free Report) last released its quarterly earnings data on Monday, November 9th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.15). Septerna had a negative net margin of 61.29% and a negative return on equity of 14.98%. The business had revenue of $18.88 million during the quarter, compared to the consensus estimate of $20.78 million. Research analysts anticipate that Septerna, Inc. will post -1.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SEPN has been the topic of a number of research analyst reports. HC Wainwright upped their price target on Septerna from $40.00 to $60.00 and gave the company a "buy" rating in a report on Wednesday, August 12th. JonesTrading lifted their price objective on Septerna from $43.00 to $62.00 and gave the stock a "buy" rating in a report on Thursday, August 13th. Raymond James Financial reissued a "strong-buy" rating and issued a $49.00 target price on shares of Septerna in a research report on Tuesday, August 11th. Wells Fargo & Company upped their target price on shares of Septerna from $50.00 to $61.00 and gave the company an "overweight" rating in a research note on Wednesday, November 4th. Finally, Stifel Nicolaus raised their price target on shares of Septerna from $49.00 to $60.00 and gave the company a "buy" rating in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $56.44.

Key Septerna News

Investors following SEPN have been watching these news items:

• Positive Sentiment: Analysts raised expectations for Septerna’s SEP-479 program, prompting a fair-value increase. The more optimistic outlook could support investors’ expectations for the company’s pipeline. Septerna fair-value lift as analysts raise SEP-479 expectations
• Positive Sentiment: Stifel Nicolaus raised its price target on SEPN, while another report said the shares reached a new 52-week high following an analyst upgrade—signals that may reinforce positive sentiment. Stifel Nicolaus price-target boost Shares reach a 52-week high following analyst upgrade
• Neutral Sentiment: HC Wainwright maintained its Buy rating and $60 target. Its revisions were mixed: it raised its FY2027 loss estimate to a smaller loss of $1.34 per share, but lowered its FY2026 estimate to a larger loss of $1.48 per share and also cut estimates for Q4 2026 and Q1 2027. Septerna analyst and stock information

Hedge Funds Weigh In On Septerna

Several hedge funds and other institutional investors have recently modified their holdings of the company. Sterling Capital Management LLC grew its holdings in shares of Septerna by 215.0% in the third quarter. Sterling Capital Management LLC now owns 630 shares of the company's stock worth $25,000 after acquiring an additional 430 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in Septerna in the third quarter valued at about $93,000. Covestor Ltd lifted its holdings in Septerna by 19.0% in the third quarter. Covestor Ltd now owns 2,526 shares of the company's stock valued at $98,000 after acquiring an additional 403 shares during the period. The Manufacturers Life Insurance Company bought a new position in Septerna in the second quarter valued at about $211,000. Finally, State Board of Administration of Florida Retirement System purchased a new position in Septerna in the third quarter worth about $232,000.

About Septerna

Septerna is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California. Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.